The paradigm of the etiology of serous ovarian cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper considers the hypothesis, based on morphological and molecular genetic studies, that the fallopian tube epithelium plays a role in the pathogenesis of serous ovarian cancer. It is customary to consider that the ovarian cancer arises from the germinal epithelium (or mesothelium) or the so-called inclusion cysts. Comparatively recently, there has been very strong evidence that patients with serous ovarian cancer and BRCA1/2 germinal mutations have been found to have serous intraepithelial carcinomas in the fimbrial sections of the fallopian tubes. It may be logically assumed from the findings that the fallopian tube epithelium is a source of pretumor and tumor processes in both the women having no family history of cancer and the patients with BRCA1/2 mutations.

Full Text

Restricted Access

About the authors

K. I Zhordania

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Email: kiazo2@yandex.ru
Doctor of Medicine, Ph.D. in Medical Sciences, Professor, Gynecologic Oncology

Yulia G. Payanidi

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Doctor of Medicine, Ph.D. in Medical Sciences, Professor, Gynecologic Oncology

Ekaterina V. Kalinicheva

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

doctor

References

  1. Аксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология. 2012; 1: 18-23 [Aksel E.M. Statistics of malignant tumors of female genitalia. Onkogynecology. 2012; 1: 18-23.]
  2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
  3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58: 71-96.
  4. Colgan T.J., Murphy J., Cole D.E., Narod S., Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 2001; 25: 1283-9.
  5. Korner M., Burckhardt E., Mazzucchelli L. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous highgrade carcinomas support different pathogenetic pathways. J. Pathol. 2005; 207: 20-6.
  6. Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Gershenson D.M., Silva E.G. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 2004; 28: 496-504.
  7. Kurman R.J., Shih Ie. M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 2011; 42(7): 918-31.
  8. Bowen N.J., Logani S., Dickerson E.B., Kapa L.B., Akhtar M., Benigno B.B., McDonald F. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol. Oncol. 2007; 104: 331-7.
  9. Cheng W, Liu J., Yoshida H., Rosen D., Naora H. Line ageinfidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med. 2005; 11: 531-7.
  10. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 2001; 22: 255-88.
  11. Fleming J.S., Beaugie C.R., Haviv I., Chenevix-Trench G., Tan O.L. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol. Cell. Endocrinol. 2006; 247: 4-21.
  12. Bhuyan P., Mahapatra S., Sethy S., Parida P., Satpathy S. Extraovarian primary peritoneal papillary serous carcinoma. Arch. Gynecol. Obstet. 2010; 281: 561-4.
  13. Lauchlan S.C. The secondary Mullerian system. Obstet. Gynecol. Surv. 1972; 27: 133-46.
  14. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007; 31: 161-9.
  15. Medeiros F., Muto M.G., Lee Y., Elvin J.A., Callahan M.J., Feltmate C. et al.The tubal fimbria is a preferred site for early adenocarcinoma in wome with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006; 30: 230-6.
  16. Zweemer R.P., van Diest P.J., Verheijen R.H., Ryan A., Gille J.J., Sijmons R.H. et al. Molecular evidence linking primary cancer of the fallopian tube toBRCA1 germline mutations. Gynecol. Oncol. 2000; 76: 45-50.
  17. Piek J.M., van Diest P.J., Zweemer R.P., Jansen J.W., Poort-Keesom R.J., Menko F.H. et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001; 195: 451-6.
  18. Salvador S., Rempel A., Soslow R.A., Gilks B., Huntsman D., Miller D. Chromosomal instability in fallopian tube precurs or lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol. Oncol. 2008; 110: 408-17.
  19. Carlson J. W, Miron A., Jarboe E.A., Parast M.M., Hirsch M.S., Lee Y. et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J. Clin. Oncol. 2008; 26: 4160-5.
  20. Salani R., Kurman R.J., Giuntoli R. 2nd, Gardner G., Bristow R., Wang T.L., Shih Ie.M. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int. J. Gynecol. Cancer. 2008; 18: 487-91.
  21. Жорданиа К.И., Хохлова С.В. Ранний рак яичников. Наш взгляд на проблему. Онкогинекология. 2012; 1: 51-8. [Zhordania K.I., Khokhlova S.V. Early ovarian cancer. Our approach to the problem. Oncogynecology. 2012; 1: 51-8.]
  22. Dehari R., Kurman R.J., Logani S., Shih Ie.M. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am. J. Surg. Pathol. 2007; 31(7): 1007-12.
  23. Li J., Abushahin N., Pang S., Xiang L., Chambers S.K., Fadare O., Kong B., Zheng W. Tubal origin of ‘ovarian’ low-grade serous carcinoma. Mod. Pathol. 2011; 24: 1488-99.
  24. Crum C.P Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol. Oncol. 2009; 3: 165-70.
  25. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008; 9: 1191-7.
  26. Norquist B.M., Garcia R.L., Allison K.H., Jokinen C.H., Kernochan L.E., Pizzi C.C. et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer. 2010; 116: 5261-71.
  27. Прокопенко П.Г., Борисенко С.А., Полторанина В.С., Шелепова В.М., Терентьев А.А. Опухоли яичников: особенности эволюции, распространения, диагностики и профилактики. Опухоли женской репродуктивной системы. 2011; 1: 63-9. [Prokopenko P.G., Borisenko S.A., Poltoranina V.S., Shelepova V.M., Terentyev A.A. Ovarian cancer: features of the evolution, distribution, diagnosis and prevention. Tumors of the female reproductive system. 2011; 1: 63-9.]
  28. Паяниди Ю.Г., Казубская Т.П., Сельчук В.Ю. Кашурников А.Ю., Огай Д.С., Наседкина Т.В. Гормональная контрацепция и рак: за и против. Онкогинекология. 2012; 3: 10-6. [Payanidi Yu.G., Kazubskaya T.P., Selchuk V.Yu., Kashurnikov A.Yu., Ogay D.S., Nasedkina T.V. Hormonal contraception and cancer: pros and cons. Cancers. 2012; 3: 10-6.]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies